Sermorelin is sold almost everywhere GLP-1 drugs are sold. Most of the sellers reviewed on this site run semaglutide or tirzepatide as their main business and offer sermorelin alongside it — several of the affiliate programs behind them are named for GLP-1 outright. Sitting next to a weight-loss drug on a menu is not evidence of being one, and the gap between those two things is unusually wide here.
Nothing published connects the two drugs
On September 14, 2026, PubMed returned zero records for sermorelin together with semaglutide, tirzepatide or GLP-1 in any combination. Not one paper, of any type — no trial, no review, no case report, no pharmacology note. For two drug classes routinely sold to the same customer in the same checkout, that is a striking silence, and it means questions about interaction, sequencing or stacking have no published answer at all.
Searching sermorelin with weight loss directly returns two records, and neither studies sermorelin as a weight-loss treatment. One concerns a GHRH receptor antagonist — a molecule working in the opposite direction — in cardiopulmonary injury. The other examines growth hormone response in hypothalamic amenorrhea, a condition in which weight loss is part of the clinical picture rather than the outcome being sought. A count on its own would suggest two studies exist. Reading them shows none does.
What the one trial measured was composition, not weight
The 1997 adult trial — nineteen people aged 55 to 71, five months, placebo-controlled — measured body composition, and lean body mass increased in the nine men and not in the ten women [1]. Weight itself was not the outcome, and a shift toward lean mass is not the same claim as losing weight; it is compatible with the scale not moving at all. The lean-mass result and what it does and does not cover goes through that finding in detail, and the full outcome list with the population attached to each shows where it sits among the rest.
The broader animal literature is not much help either. Eighteen records tie sermorelin to obesity, body fat or adiposity, and they are dominated by work on other GHRH analogs in animals — including one where a GHRH antagonist stimulated food intake in mice. That is a reminder that this receptor family does not point in one tidy direction.
Is sermorelin a GLP-1?
No, and the two work on unrelated systems. A GLP-1 drug mimics a gut hormone that acts on appetite and gastric emptying. Sermorelin is a GHRH analog: it signals the pituitary to release more of your own growth hormone, and the chain that sets off ends in IGF-1 rather than in appetite. They are not substitutes, they are not the same class, and neither the label nor the literature treats them as related.
There is no weight-loss dose
Since no trial has measured weight as an outcome, there is no dose established for that purpose. The trial dose was 10 micrograms per kilogram nightly in older adults [1], which describes one study rather than a protocol for anything, and how that compares with the dose sellers advertise is its own question. Any sermorelin weight-loss protocol you find has been assembled from somewhere other than the published record.
What this leaves a buyer with
If you are buying sermorelin from a GLP-1 seller and expecting it to contribute to weight loss, you are buying on a claim nobody has tested. That is not the same as a claim that has been tested and failed — sleep is the tested-and-failed one — but it is a long way from what the pairing implies.
The narrower, supportable version is that one small trial found a shift in body composition in men. If that is what you are after, it is worth reading as its own claim rather than as a weight-loss claim, and worth asking a prescriber about separately from whatever GLP-1 conversation brought you to the page.